Literature DB >> 32740683

CircRNA Hsa_circ_0001017 Inhibited Gastric Cancer Progression via Acting as a Sponge of miR-197.

Hui Li1, ChangPing Shan1, JunYe Wang1, ChengJiu Hu2.   

Abstract

BACKGROUND: Gastric cancer (GC) is one of the most common digestive system diseases and yet lacks effective therapeutic regimen. AIMS: The aim of our present research was to probe the value of hsa_circ_0001017 in GC treatment.
METHODS: qRT-PCR and Western blot were performed to detect gene and protein expressions, respectively. CCK-8 assay and clone formation assay were used to ensure the proliferation of GC cell lines. Transwell assay was performed to measure the migration and invasion of GC cell lines. The relationship between hsa_circ_0001017 and miR-197 and that between miR-197 and RHOB 3'-UTR were ensured using the luciferase reporter assay.
RESULTS: Decreased hsa_circ_0001017 was discovered in GC, and upregulation of hsa_circ_0001017 notably repressed proliferation, migration, and invasion of GC cell lines. We further certificated that hsa_circ_0001017 served as miR-197 sponge and suppressed the expression of miR-197. Moreover, hsa_circ_0001017 upregulation meaningfully accelerated RHOB expression in both gene and protein levels, and RHOB was a downstream target of miR-197. Overexpression of miR-197 could markedly restrain hsa_circ_0001017-induced RHOB increasing and stifle inhibition of hsa_circ_0001017 to the malignant phenotype of GC cell lines. Next, our results further confirmed that hsa_circ_0001017 increasing notably inhibited tumor growth, impeded miR-197 production, while it enhanced the expression of RHOB in vivo.
CONCLUSION: Our data demonstrated that upregulation of hsa_circ_0001017 could notably muffle the proliferation as well as the metastasis of GC cell lines and impede the formation of GC tumor via targeting to miR-197/RHOB signaling pathway. Our results evidenced that hsa_circ_0001017 may act as a rising biomarker for GC treatment.

Entities:  

Keywords:  Competing endogenous RNA; Gastric cancer; Hsa_circ_0001017; Ras homolog family member B; miR-197

Year:  2020        PMID: 32740683     DOI: 10.1007/s10620-020-06516-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  3 in total

1.  Hsa_circ_0065149 is an Indicator for Early Gastric Cancer Screening and Prognosis Prediction.

Authors:  Yongfu Shao; Xueping Tao; Rongdan Lu; Haiqiang Zhang; Jiaxin Ge; Bingxiu Xiao; Guoliang Ye; Junming Guo
Journal:  Pathol Oncol Res       Date:  2019-08-20       Impact factor: 3.201

Review 2.  MicroRNA biogenesis, gene silencing mechanisms and role in breast, ovarian and prostate cancer.

Authors:  Sanna Khan; Humaira Ayub; Taous Khan; Fazli Wahid
Journal:  Biochimie       Date:  2019-09-04       Impact factor: 4.079

Review 3.  Progress in the treatment of advanced gastric cancer.

Authors:  Zheyu Song; Yuanyu Wu; Jiebing Yang; Dingquan Yang; Xuedong Fang
Journal:  Tumour Biol       Date:  2017-07
  3 in total
  5 in total

1.  circFCHO2 promotes gastric cancer progression by activating the JAK1/STAT3 pathway via sponging miR-194-5p.

Authors:  Zhe Zhang; Chengying Sun; Yan Zheng; Yanying Gong
Journal:  Cell Cycle       Date:  2022-06-16       Impact factor: 5.173

2.  MiR-223 Promotes Tumor Progression via Targeting RhoB in Gastric Cancer.

Authors:  You Hu; Bin Yi; Xin Chen; Lu Xu; Xiaojun Zhou; Xinguo Zhu
Journal:  J Oncol       Date:  2022-01-06       Impact factor: 4.375

3.  Hsa_circ_0001017 promotes cell proliferation, migration and invasion in osteosarcoma by sponging miR-145-5p.

Authors:  Qinglei Yang; Hongying Yu; Konghe Hu
Journal:  J Orthop Surg Res       Date:  2022-03-28       Impact factor: 2.359

4.  Identification of circRNA_001846 as putative non-small cell lung cancer biomarker.

Authors:  Fan Yang; Chunlan Ma; Jing Qiu; Xiaoli Feng; Kai Yang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 5.  Circular RNAs in gastrointestinal cancer: Current knowledge, biomarkers and targeted therapy (Review).

Authors:  Xiaorui Zhao; Yue Wang; Qiongfang Yu; Pei Yu; Qiaoyu Zheng; Xue Yang; Dian Gao
Journal:  Int J Mol Med       Date:  2020-09-16       Impact factor: 4.101

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.